Cendakimab in Patients With Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial

Area of Science:

• Immunology
• Dermatology
• Clinical Trials

Background:

• Atopic dermatitis (AD) is a chronic inflammatory skin condition driven by type 2 cytokines, notably interleukin-13 (IL-13).
• Cendakimab is a selective IL-13 inhibitor designed to target this key pathway in AD pathogenesis.

Purpose of the Study:

• To evaluate the efficacy and safety of cendakimab compared to placebo in adult patients with moderate to severe AD.
• To determine the optimal dose and regimen for cendakimab treatment in AD.

Main Methods:

• A Phase 2, randomized, double-blind, placebo-controlled, dose-ranging trial involving 221 adult patients with moderate to severe AD.
• Patients received subcutaneous cendakimab (360 mg every 2 weeks, 720 mg every 2 weeks, or 720 mg weekly) or placebo for 16 weeks.
• The primary outcome measure was the mean percentage change in Eczema Area and Severity Index (EASI) scores from baseline to week 16.

Main Results:

• The 720 mg weekly dose of cendakimab met the primary efficacy endpoint, showing a significant reduction in EASI scores compared to placebo (-84.4% vs -62.7%, P=.003).
• While the 720 mg every 2 weeks dose approached significance (P=.06), the 360 mg every 2 weeks dose showed comparable effects to the weekly high dose, though statistical significance was not claimed due to hierarchical testing.
• Adverse events leading to discontinuation were low across all treatment arms.

Conclusions:

• Cendakimab, particularly at a 720 mg weekly dosage, demonstrated significant efficacy and was generally safe and well-tolerated in patients with moderate to severe AD.
• The study supports the potential of cendakimab as an effective therapeutic option for type 2 inflammatory diseases like atopic dermatitis.
• Further investigation and dose optimization may enhance its therapeutic profile.